----
Current ValuationThe current P/E ratio is 38.57, below the reasonable range, cheaper than 93.32% of the time in the past 5 years, and the industry ranks 34/173, the industry Median -0.93.
38.57xP/E
$557.93Stock price
$14.47Earnings per share
38.57xP/E
Stock price$557.93Earnings per share$14.47
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 48.46x
- Typical range
- 41.32x–56.01x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
014284256
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
ABTUSAbbott Laboratories | 33.04x | 8.68% | $178.43B |
SYKUSStryker | 31.31x | 52.68% | $116.76B |
IDXXUSIDEXX Labs | 38.57x | 12.89% | $43.95B |
DXCMUSDexCom | 32.36x | 19.08% | $32.35B |
ITGRUSInteger | 33.54x | 5.33% | $4.31B |
NVSTUSEnvista | 38.84x | 292.46% | $3.69B |
OMCLUSOmnicell | 42.59x | 2,358.33% | $1.66B |
VREXUSVarex Imaging | 35.09x | 127.65% | $775.52M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
